Lifecore Biomedical, Inc (LFCR) Fair Value & Analysis
Healthcare · US · Market cap $208M
Lifecore Biomedical, Inc
LFCR · US
Fair value as of: Jul 18, 2026
From 3 valuation models · updated today
Fair value updated Jul 18, 2026, revised from $0.1600 to $0.7200 (+350.0%) since Jun 24, 2026. Share price −15.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $3.66 – $8.82 · fair‑value band $0.5600 – $0.8600 · the $4.68 price screens above the $0.7200 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lifecore Biomedical, Inc (LFCR) currently trades at $4.68, while our model-based Fair Value estimate is $0.7200, implying the stock looks roughly 84.6% overvalued today. We read business quality at 21/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Lifecore Biomedical, Inc generated revenue of $129M at a net margin of -23.8%. Revenue declined 3.8% year over year. It earns a return on equity of -76.4%. Net debt stands at $123M. Fundamentals as of Jul 18, 2026
Our scenario range runs from $0.5600 (bear case) to $0.8600 (bull case); at $4.68, the current price sits above that range. The share trades about 48% below its 52-week high and 29% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside, at -85%, LFCR screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lifecore Biomedical, Inc reported revenue of $129M in FY2025 versus $101M in FY2021, a compound +6.3%/yr. Reported net income was −$38.7M in FY2025.
Is LFCR fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$31.94 | HK$18.00 | -44% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| Lupin Limited LUPIN | ₹2,247 | ₹2,697 | +20% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lifecore Biomedical, Inc (LFCR) undervalued?
What is the fair value of LFCR?
What is the quality score of LFCR?
What is the revenue of Lifecore Biomedical, Inc (LFCR)?
What is the net profit margin of LFCR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Lifecore Biomedical, Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.